{"id":"NCT01347073","sponsor":"Amgen","briefTitle":"Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)","officialTitle":"A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment With HPN-100, in Pediatric Subjects Under 6 Years of Age With Urea Cycle Disorders (UCDs)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2013-02","completion":"2013-03","firstPosted":"2011-05-04","resultsPosted":"2015-05-28","lastUpdate":"2024-07-11"},"enrollment":23,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Urea Cycle Disorders"],"interventions":[{"type":"DRUG","name":"HPN-100","otherNames":["RAVICTI","Glycerol phenylbuterate"]}],"arms":[{"label":"HPN-100","type":"EXPERIMENTAL"}],"summary":"This non-randomized, open-label study was approximately one year in duration and consisted of a short term NaPBA to HPN-100 switchover part involving two overnight stays followed by a 12-month long term treatment period involving monthly visits.","primaryOutcome":{"measure":"Adverse Events","timeFrame":"2 weeks","effectByArm":[{"arm":"NaPBA","deltaMin":0,"sd":null},{"arm":"HPN-100","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"29 Days","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":8},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":["24144944","23324524"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":23},"commonTop":["Upper respiratory tract infection","Vomiting","Pyrexia","Hyperammonemia","Diarrhea"]}}